Uploaded byNephroTube - Dr.Gawad
Rituximab in Nephrology (Different Uses & Available Evidence) - Dr. Gawad
The document discusses the uses of rituximab in nephrology, detailing its mechanism of action and applications in various conditions such as lupus nephritis and ANCA-associated vasculitis. It highlights findings from clinical studies, indicating that rituximab may be effective in certain cases, although recommendations for its use remain cautious due to the need for more randomized controlled trials. Additionally, the document emphasizes ongoing research and the potential for rituximab to offer benefits in treatment-resistant cases.
In this document
Powered by AI
Introduction to the presentation on rituximab and its applications in nephrology by Dr. Mohammed Abdel Gawad.
Outlines the topics covered in the presentation: mechanism of action and various nephrological conditions.
Explains the structure of rituximab and its mechanism as a monoclonal antibody targeting CD20, with references to various studies.
Outlines the topics covered in the presentation: mechanism of action and various nephrological conditions.
Explains the structure of rituximab and its mechanism as a monoclonal antibody targeting CD20, with references to various studies. Evidence regarding the use of rituximab in lupus nephritis for remission initiation and resistance.
Outlines the topics covered in the presentation: mechanism of action and various nephrological conditions.
Evidence regarding the use of rituximab in lupus nephritis for remission initiation and resistance.
Outlines the topics covered in the presentation: mechanism of action and various nephrological conditions.
Explains the structure of rituximab and its mechanism as a monoclonal antibody targeting CD20, with references to various studies.
Outlines the topics covered in the presentation: mechanism of action and various nephrological conditions.
Outlines the topics covered in the presentation: mechanism of action and various nephrological conditions.
Explains the structure of rituximab and its mechanism as a monoclonal antibody targeting CD20, with references to various studies.
Outlines the topics covered in the presentation: mechanism of action and various nephrological conditions.
Covers ongoing research and trials related to rituximab in nephrology and other related conditions.
Outlines the topics covered in the presentation: mechanism of action and various nephrological conditions.
Discusses the evidence for using rituximab in treating refractory and relapsing TTP, including key treatment strategies.
Explains the structure of rituximab and its mechanism as a monoclonal antibody targeting CD20, with references to various studies. Summarizes the main points regarding the efficacy, safety, and future direction of rituximab use in nephrology.
More Related Content
Similar to Rituximab in Nephrology (Different Uses & Available Evidence) - Dr. Gawad
Rituximab in Nephrology (Different Uses & Available Evidence) - Dr. Gawad
- 1. Rituximab in Nephrology DifferentUses & Available Evidence Mohammed Abdel Gawad Nephrology Specialist Kidney & Urology Center (KUC) Alexandria – EGY [email protected] 5th - Feb - 2018
- 2. To get thepresentation with full animations and videos please contact me on [email protected] For more presentations visit www.NephroTubeCNE.com
- 3. Talk Outline • Mechanismof action • Lupus nephritis • ANCA associated vasculitis • Primary glomerular diseases • Thrombotic thrombocytopenic purpura • Renal transplantation
- 4. Talk Outline • Mechanismof action • Lupus nephritis • ANCA associated vasculitis • Primary glomerular diseases • Thrombotic thrombocytopenic purpura • Renal transplantation
- 5. Rituximab Structure • agenetically engineered chimeric monoclonal antibody directed against the CD20 antigen. 2012; 12: 223–233. • induces apoptosis or cell lysis through complement dependent & independent mechanisms.
- 6.
- 7.
- 8. Talk Outline • Mechanismof action • Lupus nephritis • ANCA associated vasculitis • Primary glomerular diseases • Thrombotic thrombocytopenic purpura • Renal transplantation
- 9. Talk Outline • Mechanismof action • Lupus nephritis • ANCA associated vasculitis • Primary glomerular diseases • Thrombotic thrombocytopenic purpura • Renal transplantation –Initiation of remission –Resistant disease –Relapsing disease
- 10. Arthritis Rheum. 2012Apr;64(4):1215-26 144 patients with biopsy proven class III or IV LN There was no significant difference between the renal response rates at week 52 in the rituximab or placebo arms
- 11. Arthritis Rheum. 2012Apr;64(4):1215-26
- 12. Arthritis Rheum. 2012Apr;64(4):1215-26
- 13. Arthritis Rheum. 2012Apr;64(4):1215-26 However, a significantly greater improvement in serological markers
- 14.
- 15. 15, June, 2017;76:868-869 BMIwas inversely associated with renal response among patients treated with RTX
- 16.
- 17.
- 18. Methylprednisolone pulse (500 mg/m2) followedby RTX (1000 mg/1.73 m2) at days 1 and 15 MMF (1200 mg/m2/day) Prednisolone was rapidly tapered, with median dose of 0.3, 0.10 and 0.0 mg/kg/day at 3, 6 and 12 months respectively 2018 Jan;33(1):111-116
- 19.
- 20. Talk Outline • Mechanismof action • Lupus nephritis • ANCA associated vasculitis • Primary glomerular diseases • Thrombotic thrombocytopenic purpura • Renal transplantation –Initiation of remission –Resistant disease –Relapsing disease
- 22. 2013 May;22(6):574-82 At 6months, 11/18 patients reached renal CR and 2/18 PR 5 patients failed to show CR or PR despite peripheral B lymphocyte count depletion, and progressed to ESRD
- 23. 2013 Jan;28(1):106-11 Out of233 reports, we selected 26 for analysis, which described 300 patients with a mean follow-up of 60 weeks
- 24. 2013 Jan;28(1):106-11 Out of233 reports, we selected 26 for analysis, which described 300 patients with a mean follow-up of 60 weeks
- 25. 2013 Jan;28(1):106-11 Out of233 reports, we selected 26 for analysis, which described 300 patients with a mean follow-up of 60 weeks
- 26. 2013 Jan;28(1):106-11 Out of233 reports, we selected 26 for analysis, which described 300 patients with a mean follow-up of 60 weeks
- 27. Talk Outline • Mechanismof action • Lupus nephritis • ANCA associated vasculitis • Primary glomerular diseases • Thrombotic thrombocytopenic purpura • Renal transplantation –Initiation of remission –Resistant disease –Relapsing disease
- 28.
- 29.
- 30. RCT for relapsingdisease have not been performed. The long-term efficacy and toxicity of rituximab have not been defined. No suggestion or recommendation for Rituximab.
- 31. Disease Rituximab use LN(intiation of remission) • In black • Inversely related to BMI • It may allow steroid sparing in children LN (resistant) • It can be used but needs RCTs LN (relapse) • No evidence ANCA vasculitis (initiation) Not inferior to cyclophosphamide ANCA vasculitis (relapse) Superior to cyclophosphamide ANCA vasculitis (resistant) It can be used but needs RCTs ANCA vasculitis (maintenance) Superior to azathioprine Key Points
- 32. Talk Outline • Mechanismof action • Lupus nephritis • ANCA associated vasculitis • Primary glomerular diseases • Thrombotic thrombocytopenic purpura • Renal transplantation
- 33. Talk Outline • Mechanismof action • Lupus nephritis • ANCA associated vasculitis • Primary glomerular diseases • Thrombotic thrombocytopenic purpura • Renal transplantation –Initiation of remission –Relapsing disease –Resistant disease –Maintenance
- 34. © 2018 Graphic 111371Version 2.0
- 36.
- 37.
- 38. 2015 Jun;74(6):1178-8 RITUXVAS trialfollow up (p=1.00)
- 39. 2015 Jun;74(6):1178-8 RITUXVAS trialfollow up Relapses occurred in seven patients in the rituximab group (21%) and two in the control group (18%) (p=1.00)
- 40.
- 41.
- 42. Talk Outline • Mechanismof action • Lupus nephritis • ANCA associated vasculitis • Primary glomerular diseases • Thrombotic thrombocytopenic purpura • Renal transplantation –Initiation of remission –Relapsing disease –Resistant disease –Maintenance
- 44.
- 45. Talk Outline • Mechanismof action • Lupus nephritis • ANCA associated vasculitis • Primary glomerular diseases • Thrombotic thrombocytopenic purpura • Renal transplantation –Initiation of remission –Relapsing disease –Resistant disease –Maintenance
- 48. Talk Outline • Mechanismof action • Lupus nephritis • ANCA associated vasculitis • Primary glomerular diseases • Thrombotic thrombocytopenic purpura • Renal transplantation –Initiation of remission –Relapsing disease –Resistant disease –Maintenance
- 49. No suggestion or recommendation forRituximab.
- 50.
- 51. P = 0.002 (MAINRITSANtrial)
- 52.
- 53. March, 7, 2017;18: 112 h t t p : / / c l i n i c a l t r i a l s . g o v / c t 2 / s h o w /NCT01697267.
- 54. Disease Rituximab use LN(intiation of remission) • In black • Inversely related to BMI • It may allow steroid sparing in children LN (resistant) • It can be used but needs RCTs LN (relapse) • No evidence ANCA vasculitis (initiation) • Not inferior to cyclophosphamide ANCA vasculitis (relapse) • Superior to cyclophosphamide ANCA vasculitis (resistant) • It can be used but needs RCTs ANCA vasculitis (maintenance) • Superior to azathioprine Key Points
- 55. Talk Outline • Mechanismof action • Lupus nephritis • ANCA associated vasculitis • Primary glomerular diseases • Thrombotic thrombocytopenic purpura • Renal transplantation
- 56. Talk Outline • Mechanismof action • Lupus nephritis • ANCA associated vasculitis • Primary glomerular diseases • Thrombotic thrombocytopenic purpura • Renal transplantation – Membranous nephropathy – MCD & FSGS – MPGN – IgA – Anti-GBM disease
- 59.
- 60.
- 61.
- 62.
- 63.
- 64. Volume 9, 2016- Issue 11
- 65. 2017 Sep;28(9):2729-2737 4 weeklydoses of 375 mg/m2 RTX infused intravenously
- 66. 2017 Sep;28(9):2729-2737 The dashedlines describe the events in RTX-treated patients 4 weekly doses of 375 mg/m2 RTX infused intravenously
- 67. MEmbranous Nephropathy TrialOf Rituximab (MENTOR) Sequential Therapy With Tacrolimus and Rituximab in Primary Membranous Nephropathy (STARMEN) Rituximab Versus Steroids and Cyclophosphamide in the Treatment of Idiopathic Membranous Nephropathy (RI-CYCLO)
- 68. Disease Rituximab use MN• Superior to NIAT alone • Not inferior to cyclophosphamide with better safety profile • Waiting results of major ongoing trials MCD • Children: SSNS • Adults: FR, SD, SR (needs RCTs) FSGS SD but not SR (case reports) MPGN • In ig-associated MPGN, particularly in: monoclonal gammopathy chronic lymphocytic leukemia cryoglobulinemia with or without HCV • Not in C3GN or DDD IgA Case reports Anti GBM disease Case reports Key Points
- 69. Talk Outline • Mechanismof action • Lupus nephritis • ANCA associated vasculitis • Primary glomerular diseases • Thrombotic thrombocytopenic purpura • Renal transplantation – Membranous nephropathy – MCD & FSGS – MPGN – IgA – Anti-GBM disease
- 71.
- 72.
- 74. 2017 Feb; 10(1):16–19 Outcomes of all adult MCD patients treated with RTX for FRNS between 2008 and 2015were retrospectively analyzed Thirteen patients received RTX The rate of relapse was reduced from 4 to 0.4/year (Wilcoxon signed rank P ≤ 0.05)
- 75. 2017 Feb; 10(1):16–19
- 76. April, 2017, Vol.45,No. 4
- 77. April, 2017, Vol.45,No. 4
- 79. Several case reportshave described successful use of rituximab in adult patients with steroid- dependent but not steroid-resistant FSGS Oncotarget. 2017 Oct 15;8(55):93438-93443 Clin J Am Soc Nephrol. 2009 Aug;4(8):1317-23 Intern Med. 2012;51(7):759-62 Wien Klin Wochenschr. 2013 Jun;125(11-12):328-33
- 80. Disease Rituximab use MN• Superior to NIAT alone • Not inferior to cyclophosphamide with better safety profile • Waiting results of major ongoing trials MCD • Children: SSNS • Adults: FR, SD, SR (needs RCTs) FSGS • SD but not SR (case reports) MPGN • In ig-associated MPGN, particularly in: monoclonal gammopathy chronic lymphocytic leukemia cryoglobulinemia with or without HCV • Not in C3GN or DDD IgA Case reports Anti GBM disease Case reports Key Points
- 81. Talk Outline • Mechanismof action • Lupus nephritis • ANCA associated vasculitis • Primary glomerular diseases • Thrombotic thrombocytopenic purpura • Renal transplantation – Membranous nephropathy – MCD & FSGS – MPGN – IgA – Anti-GBM disease
- 82. Studies of rituximabtreatment in idiopathic MPGN Rituximab seems to be effective in immunoglobulin- associated MPGN, particularly in those cases associated with: • monoclonal gammopathy • chronic lymphocytic leukemia • cryoglobulinemia with or without HCV Biomed Res Int. May 9; 2017: 2180508.
- 83. Studies of rituximabtreatment in idiopathic MPGN Biomed Res Int. May 9; 2017: 2180508.
- 84. Reports on rituximabtreatment in C3GN and DDD Biomed Res Int. May 9; 2017: 2180508.
- 87. Mixed cryoglobulinemia syndrome +one or more of the following = immunosuppressive therapy (to rapidly improve TOD, rather than therapy directed at the underlying etiology alone) • Glomerulonephritis associated with either a rapidly progressive course and/or nephrotic range proteinuria • Severe digital ischemia threatening amputation • Gastrointestinal vasculitis associated with abdominal pain and/or gastrointestinal bleeding • Rapidly progressive neuropathy • Central nervous system vasculitis that may present as a stroke or acute cognitive impairment • Pulmonary vasculitis associated with diffuse alveolar hemorrhage or respiratory failure • Heart failure Glomerulonephritis associated with either a rapidly progressive course and/or nephrotic range proteinuria Severe digital ischemia threatening amputation Gastrointestinal vasculitis associated with abdominal pain and/or gastrointestinal bleeding Rapidly progressive neuropathy Central nervous system vasculitis that may present as a stroke or acute cognitive impairment Pulmonary vasculitis associated with diffuse alveolar hemorrhage or respiratory failure Heart failure © 2018
- 88. Rituximab for SevereMixed Cryoglobulinemia N Engl J Med. 2013 Sep;369(11):1035-45 Autoimmun Rev. 2011 Jun;10(8):444-54 Nephron Clin Pract. 2011;119(2) Immunosuppressive therapy including rituximab or, if unavailable, cyclophosphamide After disease stabilization, patients should receive concurrent therapy for the underlying disorder Exceptions to this general principle include mixed cryoglobulinemia due to HIV or HBV infections; (antiviral therapy should always be initiated before or at the same time as immunosuppressive therapy)
- 89. Disease Rituximab use MN• Superior to NIAT alone • Not inferior to cyclophosphamide with better safety profile • Waiting results of major ongoing trials MCD • Children: SSNS • Adults: FR, SD, SR (needs RCTs) FSGS SD but not SR (case reports) MPGN • In Ig-associated MPGN, particularly in: monoclonal gammopathy chronic lymphocytic leukemia cryoglobulinemia with or without HCV • Not in C3GN or DDD IgA Case reports Anti GBM disease Case reports Key Points
- 90. Talk Outline • Mechanismof action • Lupus nephritis • ANCA associated vasculitis • Primary glomerular diseases • Thrombotic thrombocytopenic purpura • Renal transplantation – Membranous nephropathy – MCD & FSGS – MPGN – IgA – Anti-GBM disease
- 91. IgA Nephropathy Ther ClinRisk Manag. 2016 Aug 29;12:1317-27
- 92. Talk Outline • Mechanismof action • Lupus nephritis • ANCA associated vasculitis • Primary glomerular diseases • Thrombotic thrombocytopenic purpura • Renal transplantation – Membranous nephropathy – MCD & FSGS – MPGN – IgA – Anti-GBM disease
- 93. Anti-GBM antibody disease SeminArthritis Rheum. 2013 Jun;42(6):567-72 J Autoimmun. 2015;60:74. Patients who either refuse or, because of severe side effects, need to discontinue cyclophosphamide may receive rituximab therapy or, alternatively, MMF. Several reported cases
- 94. Anti-GBM antibody disease SeminArthritis Rheum. 2013 Jun;42(6):567-72 J Autoimmun. 2015;60:74. initial seven consecutive days of plasma exchange and glucocorticoids two rituximab doses another seven days of plasma exchange second of the two doses of rituximab
- 95. Disease Rituximab use MN• Superior to NIAT alone • Not inferior to cyclophosphamide with better safety profile • Waiting results of major ongoing trials MCD • Children: SSNS • Adults: FR, SD, SR (needs RCTs) FSGS SD but not SR (case reports) MPGN • In Ig-associated MPGN, particularly in: monoclonal gammopathy chronic lymphocytic leukemia cryoglobulinemia with or without HCV • Not in C3GN or DDD IgA • Case reports Anti GBM disease • Case reports Key Points
- 96. Talk Outline • Mechanismof action • Lupus nephritis • ANCA associated vasculitis • Primary glomerular diseases • Thrombotic thrombocytopenic purpura • Renal transplantation
- 97. Refractory/ Relapsing TTP RefractoryTTP: Progression of clinical symptoms or persistent thrombocytopenia despite seven daily PEX procedures Relapsing TTP: Episode of acute TTP more than 30 d after remission, and occurs in 20–50% of cases. 04 British Journal of Haematology, 2012, 158, 323–335.
- 98. Refractory TTP British Journalof Haematology, 2012, 158, 323–335. 03
- 99. Relapsing TTP 03 British Journalof Haematology, 2012, 158, 323–335.
- 100. Rituximab On admission, inconjunction with PEX and steroids if: acute idiopathic TTP with neurological/cardiac pathology, which are associated with a high mortality (1B). Refractory or Relapsing immune- mediated TTP (1B). Acquired TTP Treatment Other Options 02 British Journal of Haematology, 2012, 158, 323–335.
- 101. Rituximab for initialtherapy of TTP 2011 Aug 18;118(7):1746-53
- 102. 2011 Aug 18;118(7):1746-53 Rituximabfor initial therapy of TTP
- 103. 2016 Jun 16;127(24):3092-4 Rituximabfor initial therapy of TTP
- 104. 2016 Jun 16;127(24):3092-4 Rituximabfor initial therapy of TTP
- 105. Disease Rituximab use TTP(refractory, relapse) • Good evidence to use TTP (induction of remission) • Ongoing trend Tx • Induction/desensitization in Ab incompatible Tx • Acute and chronic ABMR ??!! • Recurrent GN • PTLD Key Points
- 106. Talk Outline • Mechanismof action • Lupus nephritis • ANCA associated vasculitis • Primary glomerular diseases • Thrombotic thrombocytopenic purpura • Renal transplantation
- 107. • Induction/desensitization inAb incompatible Tx – ABO blood group incompatible transplantation – HLA antibody incompatible transplantation • Acute and chronic ABMR • Recurrent GN • PTLD 2018 Jan;102(1):44-58
- 108.
- 109.
- 110.
- 111.
- 112.
- 113. Disease Rituximab use TTP(refractory, relapse) Good evidence to use TTP (induction of remission) Ongoing trend Tx • Induction/desensitization in Ab incompatible Tx • Acute and chronic ABMR ??!! • Recurrent GN • PTLD Key Points
- 114.
- 115. • Rituximab isa chimeric monoclonal antibody directed against the CD20 antigen on the surface of immature and mature B cells. • It is used in clinical nephrology related diseases & renal transplantation. • It is safe and well tolerated in most. Key Points
- 116. • Long-term usemay be complicated by hypogammaglobulinaemia and increased infectious complications. • Optimal dosing is unclear. • The development of bio-similars and dosing targeted to B-cell response may reduce cost. Key Points
- 117. Disease Rituximab use LN(intiation of remission) • In black • Inversely related to BMI • It may allow steroid sparing in children LN (resistant) • It can be used but needs RCTs LN (relapse) • No evidence ANCA vasculitis (initiation) • Not inferior to cyclophosphamide ANCA vasculitis (relapse) • Superior to cyclophosphamide ANCA vasculitis (resistant) • It can be used but needs RCTs ANCA vasculitis (maintenance) • Superior to azathioprine Key Points
- 118. Disease Rituximab use MN• Superior to NIAT alone • Not inferior to cyclophosphamide with better safety profile • Waiting results of major ongoing trials MCD • Children: SSNS • Adults: FR, SD, SR (needs RCTs) FSGS SD but not SR (case reports) MPGN • In Ig-associated MPGN, particularly in: monoclonal gammopathy chronic lymphocytic leukemia cryoglobulinemia with or without HCV • Not in C3GN or DDD IgA • Case reports Anti GBM disease • Case reports Key Points
- 119. Disease Rituximab use TTP(refractory, relapse) • Good evidence to use TTP (induction of remission) • Ongoing trend Tx • Induction/desensitization in Ab incompatible Tx • Acute and chronic ABMR ??!! • Recurrent GN • PTLD Key Points
- 120.